Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics [Seeking Alpha]
Bioventus Inc. - Class A (BVS)
Company Research
Source: Seeking Alpha
CEO Robert Claypoole highlighted that "Bioventus delivered another solid quarter and concluded a successful year across our strategic priorities while helping patients recover so they can live life to the fullest." He Quick Insights Bioventus will drive growth with increased investments in peripheral nerve stimulation (PNS), platelet-rich plasma (PRP), ultrasonics, and international expansion, with PNS receiving the largest investment share due to market potential. Bioventus projects 2026 net sales of $600-610 million, adjusted EPS of $0.73-0.77, record cash flow from operations, improved EBITDA margins, and plans further debt reduction, reinforcing management's confidence in sustainable growth and profitability. Risks include foreign exchange losses, tariffs, lower Q1 2026 revenue due to fewer selling days and inventory normalization; mitigation strategies focus on operational efficiency and profitability. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
BVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVS alerts
High impacting Bioventus Inc. - Class A news events
Weekly update
A roundup of the hottest topics
BVS
News
- Bioventus (BVS) had its price target raised by Barrington Research from $13.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Bioventus (BVS) had its price target raised by Craig Hallum from $15.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Bioventus Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Bioventus (BVS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
BVS
Earnings
- 3/5/26 - Beat
BVS
Sec Filings
- 3/13/26 - Form 4
- 3/11/26 - Form 144
- 3/5/26 - Form S-8
- BVS's page on the SEC website